Matches in Wikidata for { <http://www.wikidata.org/entity/Q85300346> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q85300346 description "article scientifique publié en 2012" @default.
- Q85300346 description "artículu científicu espublizáu n'ochobre de 2012" @default.
- Q85300346 description "scientific article published on 26 October 2012" @default.
- Q85300346 description "wetenschappelijk artikel" @default.
- Q85300346 description "наукова стаття, опублікована в жовтні 2012" @default.
- Q85300346 name "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 name "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 type Item @default.
- Q85300346 label "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 label "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 prefLabel "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 prefLabel "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros" @default.
- Q85300346 P1433 Q85300346-B5CF973D-9121-420A-81F4-B34457992112 @default.
- Q85300346 P1476 Q85300346-60A8C58C-475A-4C83-A544-C4E951B58C67 @default.
- Q85300346 P2093 Q85300346-256698DD-A8D1-4CDE-A3A0-DE1EFFFEA57B @default.
- Q85300346 P2093 Q85300346-25C0FFFC-4E2A-48F7-A8F5-35F27EF25444 @default.
- Q85300346 P2093 Q85300346-5F0E8D6E-005F-46CC-BF21-47A4D2C588E4 @default.
- Q85300346 P2093 Q85300346-794FCC49-6FAB-4650-A1C9-D9300F68A375 @default.
- Q85300346 P2093 Q85300346-7B851929-A7E1-4ECC-B2F1-39A467ADE1EC @default.
- Q85300346 P2093 Q85300346-AF1424C9-97EB-4C00-B527-87217F374FF3 @default.
- Q85300346 P2093 Q85300346-B1E9E690-2421-403C-BBCA-D2DD2C50D2C1 @default.
- Q85300346 P2093 Q85300346-BBC04EF9-A17C-4E3B-A645-D50927BFAD60 @default.
- Q85300346 P2093 Q85300346-BF2B9FB8-6888-4116-B075-8BDAACB806E1 @default.
- Q85300346 P2093 Q85300346-CC3F1312-511F-4762-81B6-E390F2D498DD @default.
- Q85300346 P2093 Q85300346-FC8019E4-A4EE-4369-B9C2-D9B90C4E504E @default.
- Q85300346 P304 Q85300346-E26B5E93-BE56-40C9-97C2-71D1B0F1D0CC @default.
- Q85300346 P31 Q85300346-61EFB8F6-8B2D-4AC0-A4D2-D1C07FCC5672 @default.
- Q85300346 P356 Q85300346-E0893174-DAE8-4337-ABFC-3A9D757AFE5E @default.
- Q85300346 P433 Q85300346-BD2DBB2A-05AE-4A18-8ABB-63472C536E13 @default.
- Q85300346 P478 Q85300346-F9F481E4-F1AD-40B6-9BA4-B2DFE7C6C270 @default.
- Q85300346 P577 Q85300346-507FBC07-E393-441C-A8BC-113E84BC279C @default.
- Q85300346 P698 Q85300346-66162FD3-90EB-455C-995C-7C3051F20F33 @default.
- Q85300346 P921 Q85300346-1FE68E83-2C09-4A8D-83ED-C08C1C5D8056 @default.
- Q85300346 P921 Q85300346-B8DC7D34-39A4-44CA-8B20-8EAE23122044 @default.
- Q85300346 P356 MDS505 @default.
- Q85300346 P698 23104724 @default.
- Q85300346 P1433 Q326122 @default.
- Q85300346 P1476 "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer" @default.
- Q85300346 P2093 "A Heidenreich" @default.
- Q85300346 P2093 "A Stenzl" @default.
- Q85300346 P2093 "C J de Boer" @default.
- Q85300346 P2093 "D Schrijvers" @default.
- Q85300346 P2093 "F Dawkins" @default.
- Q85300346 P2093 "G Wang" @default.
- Q85300346 P2093 "K Szkarlat" @default.
- Q85300346 P2093 "L Dirix" @default.
- Q85300346 P2093 "M Welslau" @default.
- Q85300346 P2093 "N Bogdanova" @default.
- Q85300346 P2093 "S K Rawal" @default.
- Q85300346 P304 "329-336" @default.
- Q85300346 P31 Q13442814 @default.
- Q85300346 P356 "10.1093/ANNONC/MDS505" @default.
- Q85300346 P433 "2" @default.
- Q85300346 P478 "24" @default.
- Q85300346 P577 "2012-10-26T00:00:00Z" @default.
- Q85300346 P698 "23104724" @default.
- Q85300346 P921 Q420436 @default.
- Q85300346 P921 Q422248 @default.